Neoleukin Therapeutics, Inc. (NASDAQ:NLTX – Get Free Report)’s share price fell 7.5% during mid-day trading on Monday . The company traded as low as $38.18 and last traded at $39.63. 290,583 shares were traded during trading, an increase of 480% from the average daily volume of 50,104 shares. The stock had previously closed at $42.84.
Neoleukin Therapeutics Trading Up 2.0%
The stock has a market capitalization of $367.27 million, a price-to-earnings ratio of -12.57 and a beta of 1.11. The firm has a 50-day moving average of $30.63 and a 200-day moving average of $24.11.
About Neoleukin Therapeutics
Neoleukin Therapeutics, Inc is a clinical‐stage biotechnology company focused on the design and development of de novo protein therapeutics for the treatment of cancer and immune‐mediated diseases. Leveraging computational protein engineering, the company creates novel cytokine mimetics intended to provide targeted immune activation while minimizing the toxicities associated with natural cytokines. This platform is anchored by proprietary algorithms and structure‐based design tools that enable the rapid generation of therapeutic candidates with optimized stability, affinity and specificity.
The company’s lead candidate, NL-201, is a next‐generation cytokine therapy designed to engage interleukin‐2 and interleukin‐15 receptors on immune effector cells, with the goal of enhancing anti‐tumor responses.
Further Reading
- Five stocks we like better than Neoleukin Therapeutics
- Why Johnson & Johnson’s Earnings Dip Looks Like a Buying Opportunity
- CPI Comes In Cool: Why It Could Revive These 3 Rate-Sensitive Stocks
- Why ASML’s AI Monopoly Is Still Getting Stronger
- Apple’s AI Toll Booth Thesis Faces Its Biggest Test Yet Before Earnings
Receive News & Ratings for Neoleukin Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neoleukin Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
